Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

The Coronavirus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2) is a global health emergency. As only very limited therapeutic options are clinically available, there is an urgent need for the rapid development of safe, effective, a...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Sebastian Schloer, Linda Brunotte, Jonas Goretzko, Angeles Mecate-Zambrano, Nadia Korthals, Volker Gerke, Stephan Ludwig, Ursula Rescher
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Taylor & Francis Group 2020-01-01
Цуврал:	Emerging Microbes and Infections
Нөхцлүүд:	SARS-CoV-2 IAV FIASMA fluoxetine viral entry endolysosomal interference
Онлайн хандалт:	https://www.tandfonline.com/doi/10.1080/22221751.2020.1829082
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!